Healthcare provider profile · identity verified

Mark Giglio, MD

Family Practice · BREA, CA · NPI 1134129182

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	515	159
Levothyroxine Sodium	Levothyroxine Sodium	351	90
Amlodipine Besylate	Amlodipine Besylate	334	101
Losartan Potassium	Losartan Potassium	264	81
Lisinopril	Lisinopril	196	59
Simvastatin	Simvastatin	193	56
Hydrochlorothiazide	Hydrochlorothiazide	185	53
Tamsulosin Hcl	Tamsulosin Hcl	170	55
Rosuvastatin Calcium	Rosuvastatin Calcium	167	50
Metformin Hcl	Metformin Hcl	147	44
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	136	27
Benazepril Hcl	Benazepril Hcl	121	33
Eliquis	Apixaban	121	23
Pantoprazole Sodium	Pantoprazole Sodium	119	39
Metformin Hcl Er	Metformin Hcl	108	31
Alendronate Sodium	Alendronate Sodium	106	32
Zolpidem Tartrate	Zolpidem Tartrate	102	22
Omeprazole	Omeprazole	93	38
Pravastatin Sodium	Pravastatin Sodium	89	25
Tramadol Hcl	Tramadol Hcl	88	18
Alprazolam	Alprazolam	84	23
Gabapentin	Gabapentin	81	27
Albuterol Sulfate Hfa	Albuterol Sulfate	78	34
Atenolol	Atenolol	74	20
Metoprolol Succinate	Metoprolol Succinate	72	20
Metoprolol Tartrate	Metoprolol Tartrate	70	21
Trulicity	Dulaglutide	67	13
Furosemide	Furosemide	66	23
Escitalopram Oxalate	Escitalopram Oxalate	63	19
Pioglitazone Hcl	Pioglitazone Hcl	63	16
Allopurinol	Allopurinol	60	19
Ibuprofen	Ibuprofen	59	21
Januvia	Sitagliptin Phosphate	58	11
Trazodone Hcl	Trazodone Hcl	58	14
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	57	15
Famotidine	Famotidine	57	19
Potassium Chloride	Potassium Chloride	57	18
Diazepam	Diazepam	56	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	55	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	13
Lorazepam	Lorazepam	50	11
Synthroid	Levothyroxine Sodium	50	17
Fluticasone Propionate	Fluticasone Propionate	49	21
Fluoxetine Hcl	Fluoxetine Hcl	48	12
Lovastatin	Lovastatin	48	14
Valsartan	Valsartan	47	15
Montelukast Sodium	Montelukast Sodium	46	12
Zolpidem Tartrate Er	Zolpidem Tartrate	46	suppressed
Duloxetine Hcl	Duloxetine Hcl	44	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	42	11
Azithromycin	Azithromycin	41	39
Glipizide Er	Glipizide	41	suppressed
Clopidogrel	Clopidogrel Bisulfate	40	13
Jardiance	Empagliflozin	40	11
Ezetimibe	Ezetimibe	38	suppressed
Finasteride	Finasteride	36	11
Warfarin Sodium	Warfarin Sodium	36	12
Clonazepam	Clonazepam	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	30
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Irbesartan	Irbesartan	31	suppressed
Sertraline Hcl	Sertraline Hcl	31	suppressed
Carvedilol	Carvedilol	29	suppressed
Naproxen	Naproxen	29	14
Diclofenac Sodium	Diclofenac Sodium	26	11
Baclofen	Baclofen	24	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Valacyclovir	Valacyclovir Hcl	24	14
Meloxicam	Meloxicam	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Sildenafil Citrate	Sildenafil Citrate	21	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	17
Lansoprazole	Lansoprazole	19	suppressed
Ozempic	Semaglutide	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Glipizide	Glipizide	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	15
Celecoxib	Celecoxib	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Estradiol	Estradiol	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Ramipril	Ramipril	12	suppressed
Triazolam	Triazolam	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Prednisone	Prednisone	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error